

Sepiapterin is converted intracellularly into tetrahydrobiopterin, a cofactor for several important cell-based enzymes
Censa Pharmaceuticals is developing CNSA-001 as a therapy for diseases associated with deficiencies in tetrahydrobiopterin dependent enzymatic pathways